Development of ATP-competitive mTOR inhibitors

Methods in Molecular Biology

Volumn 821, Issue , 2012, Pages 447-460

  Liu, Qingsong ^a,b   Kang, Seong A ^c   Thoreen, Carson C ^a,b   Hur, Wooyoung ^a,b   Wang, Jinhua ^a,b   Chang, Jae Won ^a,b   Markhard, Andrew ^c   Zhang, Jianming ^a,b   Sim, Taebo ^a,b   Sabatini, David M ^c,d,e   Gray, Nathanael S ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Akt; mTOR; mTORC1; mTORC2; PI3K; PIKK; Rapamycin; Torin1

Indexed keywords

1 (4 (4 PROPIONYLPIPERAZIN 1 YL) 3 (TRIFLUOROMETHYL)PHENYL) 9 (QUINOLIN 3 YL)BENZO(H)(1,6)NAPHTHYRIDIN 2(1H) ONE; 1-(4-(4-PROPIONYLPIPERAZIN-1-YL)-3-(TRIFLUOROMETHYL)PHENYL)-9-(QUINOLIN-3-YL)BENZO(H)(1,6)NAPHTHYRIDIN-2(1H)-ONE; ADENOSINE TRIPHOSPHATE; CRTC2 PROTEIN, HUMAN; MTORC1 COMPLEX, HUMAN; NAPHTHYRIDINE DERIVATIVE; PROTEIN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; CELL STRAIN HEK293; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; METHODOLOGY; MOUSE; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG DESIGN; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHYRIDINES; PROTEIN KINASE INHIBITORS; PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

MAMMALIA;

EID: 84555195333     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-430-8_29     Document Type: Article

References (19)

1. Sarbassov, D. D., Ali, S. M., Sabatini, D. M. (2005) Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603. (Pubitemid 41540408)
2. Sehgal, S. N.; Baker, H.; Vezina, C. (1975) Rapamycin (AY-22989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. antibiotics (Tokyo), 28, 727-732.
3. Rao, R. D.; Buckner, J. C.; Sarkaria, J. N. (2004) mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents. Curr. Cancer Drug. Targets. 4, 621-635. (Pubitemid 40013570)
4. Guertin, D. A., Sabatini, D.M. (2007) Defining the role of mTOR in cancer. Cancer cell, 12, 9-22. (Pubitemid 47001784)
5. Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses, A. et al (2007) Dissecting the Akt/ mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res, 13, 4964-4973. (Pubitemid 47502060)
6. Karbowniczek, M., Spittle, C.S., Morrison, T., Wu, H., Henske, E.P. (2008) mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128, 980-987. (Pubitemid 351374287)
7. Meric-Bernstam, F., Gonzalez-Angulo, A. M. (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol, 27, 2278-2287.
8. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., et al. (2009) An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-insensitive functions of mTORC1. J Biol Chem. 284, 8023-8032.
9. Wan, X., Harkavy, B., Shen, N., Grohar, P., Helman, L. J. (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 26, 1932-1940. (Pubitemid 46474636)
10. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., et al. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 6, 909-919.
11. Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Yamano, M., et al. (2007) Synthesis and biological evaluation of pyrido[3',2':4,5] furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett., 17, 2438-2442. (Pubitemid 46507793)
12. Park, S., Chapuis, N., Bardet, V., Tamburini, J., Gallay, N., Willems, L., et al. (2008) PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 22, 1698-1706.
13. García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J, 421, 29-42.
14. Yu, K., Toral-Barza, L., Shi, C., Zhang, W. G., Lucas, J., Shor, B., et al. (2009) Biochemical, cellular, and in vivo activity of novel ATPcompetitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232-6240.
15. Liu, Q., Thoreen, C. C., Wang, J., Sabatini, D. M., Gray, N. S. (2009) mTOR medicated anti-cancer drug discovery. Drug. Discov. Today: Therapeutic Strategies. 6, 47-55.
16. Ding, S., Gray, N. S., Wu, X., Ding, Q., Schultz, P. G. (2002) A combinatorial scaf-fold approach toward kinase-directed heterocycle libraries. J. Am. Chem. Soc., 124, 1594-1596. (Pubitemid 34173880)
17. Liu, Q., Chang, J., Wang, J., Kang, S. A., Thoreen, C.C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., Gray, N. S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl) benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mTOR inhibitor for the treatment of cancer. J. Med. Chem. DOI: 10.1021/jm101144f
18. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871 (Pubitemid 44804279)
19. Trott, O., Olson, A. J. (2010) Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31, 455-461.